HOTH
Hoth Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.80
−2.22%Price chart
Jul 31Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$15.33M
MomentumView details →
1D Return
−2.22%
YTD Return
−30.56%
RSI (14)
31.9
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
Market Cap
$15.33M
RSI (14)
31.9
MomentumView details →
1D Return
−2.22%
YTD Return
−30.56%
SummaryUpdated Jun 1, 2026
Hoth Therapeutics, Inc. (NASDAQ:HOTH) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in New York, New York. The company went public in February 2019 and focuses on developing innovative therapies for unmet medical needs across multiple therapeutic areas. Named after the ice planet from Star Wars, Hoth operates as a development-stage biotechnology company with no current revenue, dedicating its resources to advancing a diverse pipeline of drug candidates through clinical trials and regulatory processes.
Similar companies
Latest newsMore news →
No recent news for HOTH.